Hot Topic: Direkte orale Antikoagulanzien (DOACs) beim Antiphospholipidsyndrom?

Hot topic: direct oral anticoagulants (DOAC) in antiphospholipid syndrome?

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S (2018) Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 17(10):1011–1021. https://doi.org/10.1016/j.autrev.2018.04.009

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA (2016) RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3(9):e426–e436. https://doi.org/10.1016/S2352-3026

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365–1371. https://doi.org/10.1182/blood-2018-04-848333

    Article  PubMed  CAS  Google Scholar 

  4. 4.

    Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2019-215213

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Woller SC, Stevens SM, Kaplan DA, Rondina TM (2018) Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin Appl Thromb Hemost 24(1):192. https://doi.org/10.1177/1076029617729214

    Article  PubMed  Google Scholar 

  6. 6.

    Cortés-Hernández J, Sáez-Comet L, Riera Mestre A, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaría V, Mauri Plana M, Ordi-Ros J (2018) Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome: a randomized, multicenter, open-label, clinical trial [abstract #174. Arthritis Rheumatol 70(suppl 10)

  7. 7.

    https://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019-31.html. Zugegriffen: 27.05.2019

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Dr. med. C. Specker.

Ethics declarations

Interessenkonflikt

C. Specker, T. Dörner und M. Schneider geben an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

U. Müller-Ladner, Bad Nauheim

U. Lange, Bad Nauheim

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Specker, C., Dörner, T. & Schneider, M. Hot Topic: Direkte orale Antikoagulanzien (DOACs) beim Antiphospholipidsyndrom?. Z Rheumatol 78, 493–494 (2019). https://doi.org/10.1007/s00393-019-0657-0

Download citation